Histopathological and functional changes in a single-dose model of combretastatin A4 disodium phosphate-induced
Ryota Tochinai1,2, Kayoko Komatsu1, Junta Murakami1
1Yakult Central Institute, Yakult Honsha Co., Ltd., 5-11 Izumi, Kunitachi-shi, Tokyo 186-8650, Japan.
Abstract:
Cardiotoxicity is a concern in the development of microtubule-disassembling agents (MDAs) as vascular-disrupting agents of tumors. This study investigated cardiotoxicity in rats induced by a single-dose of combretastatin A4 disodium phosphate (CA4DP), an MDA and discussed the use of this rat model in nonclinical studies of MDAs. First, CA4DP (120 mg/kg) was administered to rats intravenously, and cardiac histopathology and blood biomarkers were examined after 0.5, 24, and 72 h. Next, CA4DP (120 mg/kg) was administered to rats intravenously, and the electrocardiography and echocardiography results were analyzed. The results showed that at 0.5 h after dosing, plasma creatine kinase (CK), CK-muscle/brain (CK-MB), and fatty acid binding protein 3 levels increased. At 24 h, lactate dehydrogenase (LDH)-1, CK, and CK-MB levels increased, and multifocal vacuolar degeneration of myocardial cells was observed in the apical inner layer. At 72 h, LDH-1 levels were increased, and multifocal myocardial necrosis was observed in the interventricular septum and inner layer of the apex of left ventricular wall. Furthermore, at 0.5 h, heart rate (HR), ejection fraction (EF), and cardiac output (CO) decreased. At 24 h, CO decreased. Finally, at 72 h, HR, EF, and CO decreased, and depression of the T-wave amplitude was observed. In conclusion, myocardial injury, bradycardia, and depressed cardiac function were induced in rats by a single-dose of CA4DP. The lesion distribution and electrocardiographic features suggested that myocardial injury was induced by ischemia. These findings are similar to MDA-induced cardiotoxicity in humans, and this rat model will prove useful in studies of the cardiotoxicity in humans.
Insights
A single dose of combretastatin A4 disodium phosphate (CA4DP) induced myocardial injury, bradycardia, and reduced cardiac function in rats. This rat model is valuable for studying microtubule-disassembling agent (MDA) cardiotoxicity in humans.
Area of Science:
- Pharmacology
- Toxicology
- Cardiology
Background:
- Cardiotoxicity is a significant concern for microtubule-disassembling agents (MDAs) used as tumor vascular-disrupting agents.
- Combretastatin A4 disodium phosphate (CA4DP) is an MDA with potential anticancer applications.
Purpose of the Study:
- To investigate the cardiotoxicity induced by a single dose of CA4DP in a rat model.
- To evaluate the utility of this rat model for nonclinical studies of MDA-induced cardiotoxicity.
Main Methods:
- Rats received a single intravenous dose of CA4DP (120 mg/kg).
- Cardiac histopathology, blood biomarkers (CK, CK-MB, FABP3, LDH-1), electrocardiography (ECG), and echocardiography were assessed at 0.5, 24, and 72 hours post-administration.
Main Results:
- CA4DP administration led to increased cardiac enzyme levels (CK, CK-MB, LDH-1) and elevated fatty acid binding protein 3.
- Histopathology revealed multifocal vacuolar degeneration and myocardial necrosis.
- ECG and echocardiography showed decreased heart rate, ejection fraction, and cardiac output, with T-wave depression.
Conclusions:
- A single dose of CA4DP induces myocardial injury, bradycardia, and impaired cardiac function in rats.
- The observed myocardial injury pattern suggests an ischemic mechanism.
- This rat model effectively mimics human MDA-induced cardiotoxicity, proving useful for preclinical safety assessments.
Related Concept Videos
Bioavailability Study Design: Single Versus Multiple Dose Studies
Phosphate Buffer
Sodium dihydrogen phosphate does not fully dissociate in neutral or acidic solutions. When a strong base, such as sodium hydroxide (NaOH), is introduced into the solution, sodium dihydrogen phosphate...
Induced-fit Model
Enzymes exhibit substrate specificity, meaning that they can only bind to certain substrates. This is mainly determined by the shape and chemical...
Functional Groups
Dose Size and Dosing Frequency: Determination Methods
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses


